You are here
Roflumilast Data Submitted for European Approval
"COPD and asthma are severe diseases which are two of the most frequent causes of death. Therefore we are delighted that we have developed a new therapy which shall offer patients a safe and effective option to existing therapies," said Dr. Hans-Joachim Lohrisch, Member of the Management Board of ALTANA AG and CEO of ALTANA Pharma.
Daxas® is being developed with Pfizer Inc in the United States and other markets. A cooperation agreement has also been made with Tanabe Seiyaku in Japan.
Source: Altana AG